DVA Quote, Financials, Valuation and Earnings

Encompass Health has a net margin of 7.87% compared to DaVita's net margin of 8.61%. DaVita's return on equity of 38.64% beat Encompass Health's return on equity of 17.79%.

DaVita has a consensus price target of $164.57, signalling upside risk potential of 5.83%. On the other hand Encompass Health has an analysts' consensus of $117.18 which suggests that it could grow by 14.69%. Given that Encompass Health has higher upside potential than DaVita, analysts believe Encompass Health is more attractive than DaVita.

DaVita has a beta of 1.044, which suggesting that the stock is 4.414% more volatile than S&P 500. In comparison Encompass Health has a beta of 0.882, suggesting its less volatile than the S&P 500 by 11.77%.

DaVita has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Encompass Health offers a yield of 0.65% to investors and pays a quarterly dividend of $0.17 per share. DaVita pays -- of its earnings as a dividend. Encompass Health pays out 13.78% of its earnings as a dividend. Encompass Health's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

DaVita quarterly revenues are $3.3B, which are larger than Encompass Health quarterly revenues of $1.4B. DaVita's net income of $259.3M is higher than Encompass Health's net income of $120.9M. Notably, DaVita's price-to-earnings ratio is 14.48x while Encompass Health's PE ratio is 22.91x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for DaVita is 1.06x versus 1.94x for Encompass Health. Usually stocks with elevated PS ratios are considered overvalued.

Option Care Health has a net margin of 7.87% compared to DaVita's net margin of 4.47%. DaVita's return on equity of 38.64% beat Option Care Health's return on equity of 14.93%.

DaVita has a consensus price target of $164.57, signalling upside risk potential of 5.83%. On the other hand Option Care Health has an analysts' consensus of $38.44 which suggests that it could grow by 21.85%. Given that Option Care Health has higher upside potential than DaVita, analysts believe Option Care Health is more attractive than DaVita.

DaVita has a beta of 1.044, which suggesting that the stock is 4.414% more volatile than S&P 500. In comparison Option Care Health has a beta of 1.074, suggesting its more volatile than the S&P 500 by 7.353%.

DaVita has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Option Care Health offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. DaVita pays -- of its earnings as a dividend. Option Care Health pays out -- of its earnings as a dividend.

DaVita quarterly revenues are $3.3B, which are larger than Option Care Health quarterly revenues of $1.3B. DaVita's net income of $259.3M is higher than Option Care Health's net income of $60.1M. Notably, DaVita's price-to-earnings ratio is 14.48x while Option Care Health's PE ratio is 25.86x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for DaVita is 1.06x versus 1.09x for Option Care Health. Usually stocks with elevated PS ratios are considered overvalued.

Surgery Partners has a net margin of 7.87% compared to DaVita's net margin of -12.55%. DaVita's return on equity of 38.64% beat Surgery Partners's return on equity of -4.8%.

DaVita has a consensus price target of $164.57, signalling upside risk potential of 5.83%. On the other hand Surgery Partners has an analysts' consensus of $31.36 which suggests that it could grow by 49.42%. Given that Surgery Partners has higher upside potential than DaVita, analysts believe Surgery Partners is more attractive than DaVita.

DaVita has a beta of 1.044, which suggesting that the stock is 4.414% more volatile than S&P 500. In comparison Surgery Partners has a beta of 2.399, suggesting its more volatile than the S&P 500 by 139.885%.

DaVita has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Surgery Partners offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. DaVita pays -- of its earnings as a dividend. Surgery Partners pays out -- of its earnings as a dividend.

DaVita quarterly revenues are $3.3B, which are larger than Surgery Partners quarterly revenues of $864.4M. DaVita's net income of $259.3M is higher than Surgery Partners's net income of -$108.5M. Notably, DaVita's price-to-earnings ratio is 14.48x while Surgery Partners's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for DaVita is 1.06x versus 0.85x for Surgery Partners. Usually stocks with elevated PS ratios are considered overvalued.

US Physical Therapy has a net margin of 7.87% compared to DaVita's net margin of 4.12%. DaVita's return on equity of 38.64% beat US Physical Therapy's return on equity of 3.86%.

DaVita has a consensus price target of $164.57, signalling upside risk potential of 5.83%. On the other hand US Physical Therapy has an analysts' consensus of $108.33 which suggests that it could grow by 56.21%. Given that US Physical Therapy has higher upside potential than DaVita, analysts believe US Physical Therapy is more attractive than DaVita.

DaVita has a beta of 1.044, which suggesting that the stock is 4.414% more volatile than S&P 500. In comparison US Physical Therapy has a beta of 1.376, suggesting its more volatile than the S&P 500 by 37.634%.

DaVita has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. US Physical Therapy offers a yield of 2.55% to investors and pays a quarterly dividend of $0.45 per share. DaVita pays -- of its earnings as a dividend. US Physical Therapy pays out 100.3% of its earnings as a dividend.

DaVita quarterly revenues are $3.3B, which are larger than US Physical Therapy quarterly revenues of $180.4M. DaVita's net income of $259.3M is higher than US Physical Therapy's net income of $7.4M. Notably, DaVita's price-to-earnings ratio is 14.48x while US Physical Therapy's PE ratio is 37.69x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for DaVita is 1.06x versus 1.56x for US Physical Therapy. Usually stocks with elevated PS ratios are considered overvalued.